Liaflox (Ofloxacin)

Ofloxacin belongs to the fluoroquinolone class and works by inhibiting bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for DNA replication and transcription; their inhibition leads to bacterial cell death and eradication of the infection.

The specific dosing regimen for Liaflox is set by the prescribing clinician based on the severity of the infection, patient age, and response to therapy. The prescriber determines the number of drops, frequency, and duration of treatment.

Safety data for ophthalmic ofloxacin in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Prescribers should weigh potential benefits against risks and consider alternative treatments when appropriate.

To order Liaflox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Liaflox (ofloxacin) offers broad‑spectrum activity against Gram‑negative and Gram‑positive ocular pathogens, similar to other fluoroquinolone eye drops such as ciprofloxacin. Compared with older agents like chloramphenicol, ofloxacin generally provides higher potency and a lower risk of bacterial resistance, though choice depends on local susceptibility patterns and patient factors.

Liaflox should be stored below 25 °C in its original container, protected from light and moisture. Do not freeze the product. Keep the vial tightly closed when not in use and discard any solution that appears discolored or contaminated.

Liaflox is applied as eye drops directly onto the affected eye(s). The patient should wash hands before use, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops. The eye should be gently closed for a few seconds to allow absorption.

Serious adverse reactions include corneal ulceration or perforation, severe allergic responses such as angioedema or anaphylaxis, and systemic tendon toxicity (e.g., tendon rupture). Patients should be instructed to seek immediate medical attention if they experience intense eye pain, sudden vision loss, or signs of an allergic reaction.

Liaflox should not be used by individuals with a known hypersensitivity to ofloxacin, other fluoroquinolones, or any component of the formulation. Caution is also advised for patients with a history of tendon disorders, severe corneal disease, or those taking systemic fluoroquinolones concurrently.